Health-care-associated bloodstream and urinary tract infections in a network of hospitals in India : a multicentre, hospital-based, prospective surveillance study
Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Health-care-associated infections (HAIs) cause significant morbidity and mortality globally, including in low-income and middle-income countries (LMICs). Networks of hospitals implementing standardised HAI surveillance can provide valuable data on HAI burden, and identify and monitor HAI prevention gaps. Hospitals in many LMICs use HAI case definitions developed for higher-resourced settings, which require human resources and laboratory and imaging tests that are often not available.
METHODS: A network of 26 tertiary-level hospitals in India was created to implement HAI surveillance and prevention activities. Existing HAI case definitions were modified to facilitate standardised, resource-appropriate surveillance across hospitals. Hospitals identified health-care-associated bloodstream infections and urinary tract infections (UTIs) and reported clinical and microbiological data to the network for analysis.
FINDINGS: 26 network hospitals reported 2622 health-care-associated bloodstream infections and 737 health-care-associated UTIs from 89 intensive care units (ICUs) between May 1, 2017, and Oct 31, 2018. Central line-associated bloodstream infection rates were highest in neonatal ICUs (>20 per 1000 central line days). Catheter-associated UTI rates were highest in paediatric medical ICUs (4·5 per 1000 urinary catheter days). Klebsiella spp (24·8%) were the most frequent organism in bloodstream infections and Candida spp (29·4%) in UTIs. Carbapenem resistance was common in Gram-negative infections, occurring in 72% of bloodstream infections and 76% of UTIs caused by Klebsiella spp, 77% of bloodstream infections and 76% of UTIs caused by Acinetobacter spp, and 64% of bloodstream infections and 72% of UTIs caused by Pseudomonas spp.
INTERPRETATION: The first standardised HAI surveillance network in India has succeeded in implementing locally adapted and context-appropriate protocols consistently across hospitals and has been able to identify a large number of HAIs. Network data show high HAI and antimicrobial resistance rates in tertiary hospitals, showing the importance of implementing multimodal HAI prevention and antimicrobial resistance containment strategies.
FUNDING: US Centers for Disease Control and Prevention cooperative agreement with All India Institute of Medical Sciences, New Delhi.
TRANSLATION: For the Hindi translation of the abstract see Supplementary Materials section.
| Errataetall: |
CommentIn: Lancet Glob Health. 2022 Sep;10(9):e1222-e1223. - PMID 35961335 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
The Lancet. Global health - 10(2022), 9 vom: 05. Sept., Seite e1317-e1325 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mathur, Purva [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Infective Agents |
|---|
| Anmerkungen: |
Date Completed 16.08.2022 Date Revised 24.08.2022 published: Print CommentIn: Lancet Glob Health. 2022 Sep;10(9):e1222-e1223. - PMID 35961335 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2214-109X(22)00274-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344801349 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344801349 | ||
| 003 | DE-627 | ||
| 005 | 20231226023617.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2214-109X(22)00274-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344801349 | ||
| 035 | |a (NLM)35961355 | ||
| 035 | |a (PII)S2214-109X(22)00274-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mathur, Purva |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Health-care-associated bloodstream and urinary tract infections in a network of hospitals in India |b a multicentre, hospital-based, prospective surveillance study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2022 | ||
| 500 | |a Date Revised 24.08.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Lancet Glob Health. 2022 Sep;10(9):e1222-e1223. - PMID 35961335 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Health-care-associated infections (HAIs) cause significant morbidity and mortality globally, including in low-income and middle-income countries (LMICs). Networks of hospitals implementing standardised HAI surveillance can provide valuable data on HAI burden, and identify and monitor HAI prevention gaps. Hospitals in many LMICs use HAI case definitions developed for higher-resourced settings, which require human resources and laboratory and imaging tests that are often not available | ||
| 520 | |a METHODS: A network of 26 tertiary-level hospitals in India was created to implement HAI surveillance and prevention activities. Existing HAI case definitions were modified to facilitate standardised, resource-appropriate surveillance across hospitals. Hospitals identified health-care-associated bloodstream infections and urinary tract infections (UTIs) and reported clinical and microbiological data to the network for analysis | ||
| 520 | |a FINDINGS: 26 network hospitals reported 2622 health-care-associated bloodstream infections and 737 health-care-associated UTIs from 89 intensive care units (ICUs) between May 1, 2017, and Oct 31, 2018. Central line-associated bloodstream infection rates were highest in neonatal ICUs (>20 per 1000 central line days). Catheter-associated UTI rates were highest in paediatric medical ICUs (4·5 per 1000 urinary catheter days). Klebsiella spp (24·8%) were the most frequent organism in bloodstream infections and Candida spp (29·4%) in UTIs. Carbapenem resistance was common in Gram-negative infections, occurring in 72% of bloodstream infections and 76% of UTIs caused by Klebsiella spp, 77% of bloodstream infections and 76% of UTIs caused by Acinetobacter spp, and 64% of bloodstream infections and 72% of UTIs caused by Pseudomonas spp | ||
| 520 | |a INTERPRETATION: The first standardised HAI surveillance network in India has succeeded in implementing locally adapted and context-appropriate protocols consistently across hospitals and has been able to identify a large number of HAIs. Network data show high HAI and antimicrobial resistance rates in tertiary hospitals, showing the importance of implementing multimodal HAI prevention and antimicrobial resistance containment strategies | ||
| 520 | |a FUNDING: US Centers for Disease Control and Prevention cooperative agreement with All India Institute of Medical Sciences, New Delhi | ||
| 520 | |a TRANSLATION: For the Hindi translation of the abstract see Supplementary Materials section | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Anti-Infective Agents |2 NLM | |
| 700 | 1 | |a Malpiedi, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Walia, Kamini |e verfasserin |4 aut | |
| 700 | 1 | |a Srikantiah, Padmini |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Sunil |e verfasserin |4 aut | |
| 700 | 1 | |a Lohiya, Ayush |e verfasserin |4 aut | |
| 700 | 1 | |a Chakrabarti, Arunaloke |e verfasserin |4 aut | |
| 700 | 1 | |a Ray, Pallab |e verfasserin |4 aut | |
| 700 | 1 | |a Biswal, Manisha |e verfasserin |4 aut | |
| 700 | 1 | |a Taneja, Neelam |e verfasserin |4 aut | |
| 700 | 1 | |a Rupali, Priscilla |e verfasserin |4 aut | |
| 700 | 1 | |a Balaji, Veeraraghavan |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigues, Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a Lakshmi Nag, Vijaya |e verfasserin |4 aut | |
| 700 | 1 | |a Tak, Vibhor |e verfasserin |4 aut | |
| 700 | 1 | |a Venkatesh, Vimala |e verfasserin |4 aut | |
| 700 | 1 | |a Mukhopadhyay, Chiranjay |e verfasserin |4 aut | |
| 700 | 1 | |a Deotale, Vijayshri |e verfasserin |4 aut | |
| 700 | 1 | |a Padmaja, Kanne |e verfasserin |4 aut | |
| 700 | 1 | |a Wattal, Chand |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharya, Sanjay |e verfasserin |4 aut | |
| 700 | 1 | |a Karuna, Tadepalli |e verfasserin |4 aut | |
| 700 | 1 | |a Behera, Bijayini |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Sanjeev |e verfasserin |4 aut | |
| 700 | 1 | |a Nath, Reema |e verfasserin |4 aut | |
| 700 | 1 | |a Ray, Raja |e verfasserin |4 aut | |
| 700 | 1 | |a Baveja, Sujata |e verfasserin |4 aut | |
| 700 | 1 | |a Fomda, Bashir A |e verfasserin |4 aut | |
| 700 | 1 | |a Sulochana Devi, Khumanthem |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Padma |e verfasserin |4 aut | |
| 700 | 1 | |a Khandelwal, Neeta |e verfasserin |4 aut | |
| 700 | 1 | |a Verma, Prachi |e verfasserin |4 aut | |
| 700 | 1 | |a Bhattacharyya, Prithwis |e verfasserin |4 aut | |
| 700 | 1 | |a Gaind, Rajni |e verfasserin |4 aut | |
| 700 | 1 | |a Kapoor, Lata |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Aditya |e verfasserin |4 aut | |
| 700 | 1 | |a VanderEnde, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Siromany, Valan |e verfasserin |4 aut | |
| 700 | 1 | |a Laserson, Kayla |e verfasserin |4 aut | |
| 700 | 1 | |a Guleria, Randeep |e verfasserin |4 aut | |
| 700 | 0 | |a Indian Healthcare Associated Infection Surveillance Network collaborators |e verfasserin |4 aut | |
| 700 | 1 | |a Malhotra, Rajesh |e investigator |4 oth | |
| 700 | 1 | |a Katoch, Omika |e investigator |4 oth | |
| 700 | 1 | |a Katyal, Sonal |e investigator |4 oth | |
| 700 | 1 | |a Khurana, Surbhi |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Subodh |e investigator |4 oth | |
| 700 | 1 | |a Agrawal, Richa |e investigator |4 oth | |
| 700 | 1 | |a Dev Soni, Kapil |e investigator |4 oth | |
| 700 | 1 | |a Sagar, Sushma |e investigator |4 oth | |
| 700 | 1 | |a Wig, Naveet |e investigator |4 oth | |
| 700 | 1 | |a Garg, Pramod |e investigator |4 oth | |
| 700 | 1 | |a Kapil, Arti |e investigator |4 oth | |
| 700 | 1 | |a Lodha, Rakesh |e investigator |4 oth | |
| 700 | 1 | |a Sahu, Manoj |e investigator |4 oth | |
| 700 | 1 | |a Misra, M C |e investigator |4 oth | |
| 700 | 1 | |a Lamba, Mamta |e investigator |4 oth | |
| 700 | 1 | |a Jain, Shristi |e investigator |4 oth | |
| 700 | 1 | |a Paul, Hema |e investigator |4 oth | |
| 700 | 1 | |a Sarojini Michael, Joy |e investigator |4 oth | |
| 700 | 1 | |a Kumar Bhatia, Pradeep |e investigator |4 oth | |
| 700 | 1 | |a Singh, Kuldeep |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Neeraj |e investigator |4 oth | |
| 700 | 1 | |a Khera, Daisy |e investigator |4 oth | |
| 700 | 1 | |a Himanshu, D |e investigator |4 oth | |
| 700 | 1 | |a Verma, Sheetal |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Prashant |e investigator |4 oth | |
| 700 | 1 | |a Kumar, Mala |e investigator |4 oth | |
| 700 | 1 | |a Pervez Khan, Mohammed |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Sarika |e investigator |4 oth | |
| 700 | 1 | |a Kalwaje Eshwara, Vandana |e investigator |4 oth | |
| 700 | 1 | |a Varma, Muralidhar |e investigator |4 oth | |
| 700 | 1 | |a Attal, Ruchita |e investigator |4 oth | |
| 700 | 1 | |a Sudhaharan, Sukanya |e investigator |4 oth | |
| 700 | 1 | |a Goel, Neeraj |e investigator |4 oth | |
| 700 | 1 | |a Saigal, Saurabh |e investigator |4 oth | |
| 700 | 1 | |a Khadanga, Sagar |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Ayush |e investigator |4 oth | |
| 700 | 1 | |a Thirunarayan, M A |e investigator |4 oth | |
| 700 | 1 | |a Sethuraman, Nandini |e investigator |4 oth | |
| 700 | 1 | |a Roy, Ujjaini |e investigator |4 oth | |
| 700 | 1 | |a Jyoti Raj, Hirak |e investigator |4 oth | |
| 700 | 1 | |a D'Souza, Desma |e investigator |4 oth | |
| 700 | 1 | |a Chandy, Mammen |e investigator |4 oth | |
| 700 | 1 | |a Mukherjee, Sudipta |e investigator |4 oth | |
| 700 | 1 | |a Kumar Roy, Manas |e investigator |4 oth | |
| 700 | 1 | |a Goel, Gaurav |e investigator |4 oth | |
| 700 | 1 | |a Tripathy, Swagata |e investigator |4 oth | |
| 700 | 1 | |a Misra, Satyajeet |e investigator |4 oth | |
| 700 | 1 | |a Dey, Anupam |e investigator |4 oth | |
| 700 | 1 | |a Misra, Tushar |e investigator |4 oth | |
| 700 | 1 | |a Ranjan Das, Rashmi |e investigator |4 oth | |
| 700 | 1 | |a Bashir, Gulnaz |e investigator |4 oth | |
| 700 | 1 | |a Nazir, Shaista |e investigator |4 oth | |
| 700 | 1 | |a Ranjana Devi, Khuraijam |e investigator |4 oth | |
| 700 | 1 | |a Chaoba Singh, Langpoklakpam |e investigator |4 oth | |
| 700 | 1 | |a Bhargava, Anudita |e investigator |4 oth | |
| 700 | 1 | |a Gaikwad, Ujjwala |e investigator |4 oth | |
| 700 | 1 | |a Vaghela, Geeta |e investigator |4 oth | |
| 700 | 1 | |a Sukharamwala, Tanvi |e investigator |4 oth | |
| 700 | 1 | |a Ch Phukan, Anil |e investigator |4 oth | |
| 700 | 1 | |a Lyngdoh, Clarissa |e investigator |4 oth | |
| 700 | 1 | |a Saksena, Rushika |e investigator |4 oth | |
| 700 | 1 | |a Sharma, Rajeev |e investigator |4 oth | |
| 700 | 1 | |a Velayudhan, Anoop |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Global health |d 2013 |g 10(2022), 9 vom: 05. Sept., Seite e1317-e1325 |w (DE-627)NLM237515954 |x 2214-109X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g number:9 |g day:05 |g month:09 |g pages:e1317-e1325 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2214-109X(22)00274-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |e 9 |b 05 |c 09 |h e1317-e1325 | ||